MK-677 DSIP Protocol — Sleep + GH Research Mechanisms

Research published in the Journal of Clinical Endocrinology & Metabolism found that ibutamoren (MK-677) increases growth hormone secretion by 60–127% in healthy subjects while simultaneously improving sleep quality markers. Specifically delta-wave amplitude and duration. What most researchers miss: this isn't a simple GH boost. MK-677 acts as a ghrelin receptor agonist, mimicking the hunger hormone's effects on the hypothalamic-pituitary axis, which triggers pulsatile GH release identical to natural secretion patterns. When combined with delta sleep-inducing peptide (DSIP), the protocol targets two complementary mechanisms. One amplifying GH output, the other deepening the sleep architecture where endogenous GH normally peaks.

Our team has reviewed this protocol across dozens of lab studies. The mistake most researchers make isn't choosing the wrong peptides. It's misunderstanding how they interact. MK-677 and DSIP don't just coexist in a stack; they amplify each other's effects at the receptor level.

What is the MK-677 DSIP protocol for sleep and GH research?

The MK-677 DSIP protocol combines ibutamoren mesylate (a selective ghrelin receptor agonist) at 15–25mg daily with delta sleep-inducing peptide at 100–300mcg before sleep to enhance both growth hormone secretion and slow-wave sleep architecture. MK-677 elevates GH output through hypothalamic stimulation while DSIP increases delta-wave amplitude by 40–60%, creating conditions where GH pulses coincide with deeper sleep stages. The natural window for peak endogenous hormone release.

Most protocol guides describe MK-677 as 'a growth hormone booster' and DSIP as 'a sleep peptide'. Technically true but functionally incomplete. MK-677's ghrelin mimicry doesn't just raise GH levels; it restores pulsatile secretion patterns that age and metabolic dysfunction disrupt. DSIP doesn't sedate; it modulates cortisol and enhances delta-wave sleep without suppressing REM cycles. The combination addresses both sides of the recovery equation: hormonal output and neurological restoration. This article covers the exact receptor mechanisms at work, evidence-based dosing ranges from published trials, timing strategies that maximise synergy, and what preparation errors negate the stack's benefits entirely.

MK-677 Mechanism: Ghrelin Receptor Activation and GH Pulsatility

Ibutamoren (MK-677) binds to ghrelin receptors (GHSR1a) in the hypothalamus and pituitary gland, triggering a cascade that mimics endogenous ghrelin's effects on growth hormone-releasing hormone (GHRH) neurons. Unlike exogenous GH or GHRH analogues, MK-677 doesn't suppress the hypothalamic-pituitary-adrenal (HPA) axis. It works within the body's natural feedback loops. A 1997 study in the Journal of Clinical Endocrinology & Metabolism demonstrated that 25mg daily MK-677 increased mean 24-hour GH levels by 97% and IGF-1 levels by 40% in healthy young men, with no desensitisation over two months.

The pulsatile pattern matters. Natural GH secretion occurs in surges. Primarily during deep sleep and after resistance training. Synthetic GH administration delivers a sustained elevated level, which the pituitary interprets as feedback to reduce endogenous production. MK-677 preserves the pulse structure: research subjects maintained 4–6 GH peaks per day, identical to baseline frequency but with higher amplitude. This distinction explains why long-term MK-677 use doesn't cause pituitary shutdown the way exogenous hormones do.

Ghrelin receptors in the arcuate nucleus of the hypothalamus also regulate appetite and energy expenditure. MK-677 consistently increases hunger. Subjects in clinical trials report 20–30% higher caloric intake on average. For research focused on muscle anabolism or metabolic health, this is a feature, not a bug. For studies prioritising fat loss or caloric restriction, it's a confounding variable that must be controlled.

DSIP Mechanism: Delta-Wave Modulation and Cortisol Regulation

Delta sleep-inducing peptide (DSIP) was first isolated from rabbit cerebral tissue in 1974 and shown to induce delta-wave sleep without sedation or addiction potential. Unlike GABAergic sedatives (benzodiazepines, Z-drugs), DSIP doesn't suppress REM sleep or create tolerance. Instead, it modulates the hypothalamic-pituitary-adrenal axis by reducing evening cortisol and enhancing the transition from light sleep (stages 1–2) to slow-wave sleep (stage 3).

Polysomnographic studies in humans found that DSIP administration (100–200mcg intranasally or subcutaneously) increased delta-wave amplitude by 40–60% without altering total sleep time or REM percentage. The mechanism involves serotonergic and dopaminergic modulation in the raphe nuclei and locus coeruleus. Brain regions that regulate arousal and sleep architecture. DSIP doesn't knock you out; it deepens the quality of sleep you already achieve naturally.

Cortisol suppression is the secondary effect most relevant to GH research. Elevated evening cortisol. Common in chronic stress, shift work, or aging. Blunts GH secretion by antagonising GHRH signalling. DSIP lowers evening cortisol by approximately 20–35% in studies measuring salivary and serum levels, creating a more permissive hormonal environment for GH release. This is where the synergy with MK-677 becomes mechanistic: MK-677 provides the signal (ghrelin receptor activation), and DSIP removes the brake (cortisol suppression).

Protocol Design: Dosing, Timing, and Administration Routes

Standard research protocols use MK-677 at 15–25mg once daily, typically administered in the evening 60–90 minutes before sleep. The half-life is approximately 4–6 hours, with peak plasma levels occurring 90 minutes post-administration. Evening dosing aligns the GH pulse with the body's natural nocturnal surge, which occurs 60–90 minutes after sleep onset during the first slow-wave sleep cycle.

DSIP dosing ranges from 100–300mcg, administered subcutaneously or intranasally 30–45 minutes before bed. Subcutaneous administration shows higher bioavailability (estimated 70–85% vs 40–60% intranasal), but nasal delivery avoids injection site discomfort and achieves faster onset. Most researchers find 150–200mcg subcutaneous to be the effective range. Below 100mcg shows minimal polysomnographic changes, and above 300mcg doesn't yield proportional benefit.

Timing sequence: DSIP first (30–45 minutes pre-sleep), then MK-677 (60–90 minutes pre-sleep). This stagger ensures DSIP begins modulating cortisol and sleep architecture before MK-677's GH pulse peaks. If both are administered simultaneously, you risk MK-677's appetite-stimulating effects interfering with sleep onset. Subjects report increased hunger making it harder to fall asleep if dosed too close to bedtime without accounting for this lag.

Reconstitution and storage: MK-677 is typically supplied as capsules or powder for oral administration. No reconstitution needed. DSIP arrives as lyophilised powder requiring reconstitution with bacteriostatic water. Standard concentration: 2mg DSIP per 2mL bacteriostatic water yields 1mg/mL, meaning a 200mcg dose requires 0.2mL (20 units on an insulin syringe). Store reconstituted DSIP at 2–8°C and use within 28 days.

MK-677 DSIP Protocol: Peptide Comparison

This table compares the primary peptides in the mk-677 dsip protocol sleep + gh research stack and their distinct mechanisms.

Key Takeaways

• MK-677 acts as a ghrelin receptor agonist, increasing pulsatile GH secretion by 60–127% without suppressing the hypothalamic-pituitary axis. Preserving natural feedback loops that exogenous GH disrupts.
• DSIP enhances delta-wave sleep amplitude by 40–60% and reduces evening cortisol by 20–35%, creating a permissive hormonal environment for nocturnal GH release.
• The synergy between MK-677 and DSIP is mechanistic, not additive. Ghrelin receptor activation (MK-677) coincides with deepened slow-wave sleep (DSIP), the exact window where endogenous GH peaks naturally.
• Standard research dosing: MK-677 at 15–25mg once daily in the evening, DSIP at 100–300mcg subcutaneously 30–45 minutes before sleep.
• MK-677 increases appetite by 20–30% on average. A confounding variable in metabolic studies that must be controlled through dietary monitoring or fasting protocols.
• Reconstituted DSIP must be stored at 2–8°C and used within 28 days; temperature excursions above 8°C denature the peptide structure irreversibly.

What If: MK-677 DSIP Protocol Scenarios

What If I Experience Increased Hunger from MK-677 That Disrupts Sleep?

Reduce the MK-677 dose to 12.5–15mg and extend the pre-sleep timing window to 90–120 minutes. The ghrelin receptor activation peaks 60–90 minutes post-administration, so earlier dosing allows the appetite spike to pass before attempting sleep. If hunger persists, consume a small protein-dominant meal (20–30g protein, minimal carbohydrate) 45 minutes before bed. This blunts ghrelin signalling without spiking insulin enough to interfere with GH release. Casein protein or a small serving of cottage cheese is ideal for this purpose.

What If DSIP Doesn't Improve Subjective Sleep Quality Within the First Week?

DSIP's effects on delta-wave architecture are measurable on polysomnography before they become subjectively noticeable. Most subjects report improved sleep quality after 7–14 consecutive days, not immediately. If no improvement occurs after two weeks at 200mcg, increase to 250–300mcg or switch from intranasal to subcutaneous administration for higher bioavailability. Concurrent stressors. Caffeine intake after 2pm, inconsistent sleep timing, blue light exposure within two hours of bed. Will blunt DSIP's effectiveness regardless of dose.

What If I Want to Cycle MK-677 to Avoid Desensitisation?

MK-677 does not show receptor desensitisation in trials lasting up to 24 months. The ghrelin receptor maintains sensitivity to agonist binding without downregulation. The need to cycle is a myth borrowed from exogenous GH protocols. However, insulin sensitivity may decrease slightly with prolonged MK-677 use (fasting glucose increases by 5–10 mg/dL on average in long-term studies), so periodic glucose monitoring is prudent. If fasting glucose rises above 100 mg/dL, reduce MK-677 to 15mg or implement a 4-week break while continuing DSIP alone.

The Evidence-Based Truth About MK-677 DSIP Synergy

Here's the honest answer: the mk-677 dsip protocol sleep + gh research combination works. But not through the mechanism most supplement marketing claims. MK-677 doesn't 'build muscle while you sleep' any more than DSIP 'knocks you out instantly.' What they do is restore physiological conditions that aging, stress, and poor sleep hygiene degrade: pulsatile GH secretion and deep slow-wave sleep architecture.

The synergy is real, but it's conditional. If you run this stack while sleeping five hours a night, eating in a deficit, and training fasted, you'll see minimal benefit. MK-677 amplifies GH pulses that occur during deep sleep. If you're not achieving slow-wave sleep, there's no pulse to amplify. DSIP deepens delta waves. If cortisol is chronically elevated from overtraining or under-recovery, DSIP's modest 20–35% cortisol reduction won't overcome that.

The data from clinical trials is clear: MK-677 at 25mg daily increases mean IGF-1 by 40% and nitrogen retention improves measurably. DSIP at 200mcg increases delta-wave percentage from baseline 18–22% to 28–32% on polysomnography. Those are objective, reproducible outcomes. What they don't do is compensate for poor training design, inadequate caloric surplus, or sleep restriction.

Protocol Refinement: Variables That Determine Efficacy

The mk-677 dsip protocol sleep + gh research stack's effectiveness hinges on controlling variables most researchers overlook. Insulin sensitivity is the first one. MK-677 increases fasting glucose slightly (5–10 mg/dL) and may reduce insulin sensitivity by 10–15% over 6–12 months of continuous use. If baseline glucose regulation is already impaired. Fasting glucose above 95 mg/dL, HbA1c above 5.5%. The protocol should include metformin (500–1000mg daily) or berberine (500mg 2–3x daily) to maintain euglycemia.

Dietary protein timing matters more than total intake. MK-677 elevates GH, which stimulates muscle protein synthesis. But only in the presence of adequate leucine. The leucine threshold for mTOR activation is approximately 2.5–3g per meal. If meals contain less than this, the anabolic signal from elevated GH is wasted. Distribute protein intake across 3–4 meals (30–40g each) rather than concentrating it in one or two large servings.

Sleep hygiene is non-negotiable. DSIP enhances delta-wave sleep, but it doesn't create sleep where none exists. Consistent sleep timing (within 30 minutes daily), complete darkness (blackout curtains or eye mask), and temperature regulation (16–19°C bedroom temperature) are prerequisites. DSIP cannot override blue light exposure, caffeine after 2pm, or alcohol consumption. All of which fragment sleep architecture and blunt GH secretion regardless of peptide intervention.

For researchers using this protocol in lab settings, our experience shows that controlling for these variables. Glucose monitoring, protein timing, and sleep hygiene adherence. Determines whether results replicate across subjects or show high variance. The peptides work; the context determines the magnitude.

The highest-purity research peptides begin with exact amino-acid sequencing and small-batch synthesis. Our dedication to quality extends across our entire product line, including compounds like MK-677 that support rigorous study design. You can explore our full range of research-grade peptides to find the tools that match your specific protocols.

If the stack concerns you, start with single-peptide trials first. Run MK-677 alone for four weeks, then add DSIP. Isolating each compound clarifies which variable drives observed outcomes and eliminates confounding attribution errors common in multi-agent protocols.